Suppr超能文献

转谷氨酰胺酶催化反应的生理病理作用。

Physio-pathological roles of transglutaminase-catalyzed reactions.

作者信息

Ricotta Mariangela, Iannuzzi Maura, Vivo Giulia De, Gentile Vittorio

机构信息

Mariangela Ricotta, Maura Iannuzzi, Giulia De Vivo, Vittorio Gentile, Department of Biochemistry and Biophysics, Medical School, Second University of Naples, via Costantinopoli 16, 80138 Napoli, Italy.

出版信息

World J Biol Chem. 2010 May 26;1(5):181-7. doi: 10.4331/wjbc.v1.i5.181.

Abstract

Transglutaminases (TGs) are a large family of related and ubiquitous enzymes that catalyze post-translational modifications of proteins. The main activity of these enzymes is the cross-linking of a glutaminyl residue of a protein/peptide substrate to a lysyl residue of a protein/peptide co-substrate. In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or polyamines (to form mono- or bi-substituted /crosslinked adducts) or -OH groups (to form ester linkages). In the absence of co-substrates, the nucleophile may be water, resulting in the net deamidation of the glutaminyl residue. The TG enzymes are also capable of catalyzing other reactions important for cell viability. The distribution and the physiological roles of TG enzymes have been widely studied in numerous cell types and tissues and their roles in several diseases have begun to be identified. "Tissue" TG (TG2), a member of the TG family of enzymes, has definitely been shown to be involved in the molecular mechanisms responsible for a very widespread human pathology: i.e. celiac disease (CD). TG activity has also been hypothesized to be directly involved in the pathogenetic mechanisms responsible for several other human diseases, including neurodegenerative diseases, which are often associated with CD. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, supranuclear palsy, Huntington's disease and other recently identified polyglutamine diseases, are characterized, in part, by aberrant cerebral TG activity and by increased cross-linked proteins in affected brains. In this review, we discuss the physio-pathological role of TG-catalyzed reactions, with particular interest in the molecular mechanisms that could involve these enzymes in the physio-pathological processes responsible for human neurodegenerative diseases.

摘要

转谷氨酰胺酶(TGs)是一个相关且普遍存在的酶大家族,可催化蛋白质的翻译后修饰。这些酶的主要活性是将蛋白质/肽底物的谷氨酰胺残基与蛋白质/肽共底物的赖氨酸残基交联。除赖氨酸残基外,其他第二亲核共底物可能包括单胺或多胺(形成单取代或双取代/交联加合物)或-OH基团(形成酯键)。在没有共底物的情况下,亲核试剂可能是水,导致谷氨酰胺残基净脱酰胺。TG酶还能够催化对细胞活力重要的其他反应。TG酶的分布和生理作用已在众多细胞类型和组织中得到广泛研究,并且它们在几种疾病中的作用已开始被确定。“组织”TG(TG2)是TG酶家族的一员,已明确显示其参与导致一种非常普遍的人类病理学的分子机制,即乳糜泻(CD)。TG活性也被假设直接参与导致其他几种人类疾病的发病机制,包括通常与CD相关的神经退行性疾病。神经退行性疾病,如阿尔茨海默病、帕金森病、核上性麻痹、亨廷顿病和其他最近发现的多聚谷氨酰胺疾病,部分特征是大脑TG活性异常以及受影响大脑中交联蛋白增加。在本综述中,我们讨论TG催化反应的生理病理作用,特别关注可能使这些酶参与导致人类神经退行性疾病的生理病理过程的分子机制。

相似文献

1
Physio-pathological roles of transglutaminase-catalyzed reactions.
World J Biol Chem. 2010 May 26;1(5):181-7. doi: 10.4331/wjbc.v1.i5.181.
3
Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Recent Pat CNS Drug Discov. 2010 Nov;5(3):195-202. doi: 10.2174/157488910793362430.
4
5
Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Recent Pat CNS Drug Discov. 2013 Aug;8(2):161-8. doi: 10.2174/15748898113089990001.
6
Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
Recent Pat CNS Drug Discov. 2013 Dec;8(3):235-42. doi: 10.2174/1574889808666131128105630.
10
Pathophysiological roles of transglutaminase - catalyzed reactions in the pathogenesis of human diseases.
Inflamm Allergy Drug Targets. 2012 Aug 1;11(4):278-84. doi: 10.2174/187152812800959004.

引用本文的文献

1
Transglutaminase Type 2 regulates the Wnt/β-catenin pathway in vertebrates.
Cell Death Dis. 2021 Mar 5;12(3):249. doi: 10.1038/s41419-021-03485-2.
2
Characterisation of a novel cold-adapted calcium-activated transglutaminase: implications for medicine and food processing.
FEBS Open Bio. 2020 Apr;10(4):495-506. doi: 10.1002/2211-5463.12826. Epub 2020 Mar 16.
3
Candesartan Neuroprotection in Rat Primary Neurons Negatively Correlates with Aging and Senescence: a Transcriptomic Analysis.
Mol Neurobiol. 2020 Mar;57(3):1656-1673. doi: 10.1007/s12035-019-01800-9. Epub 2019 Dec 7.
4
Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes.
Int J Mol Sci. 2019 Nov 27;20(23):5963. doi: 10.3390/ijms20235963.
5
Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges.
Curr Neuropharmacol. 2019;17(1):33-58. doi: 10.2174/1570159X16666180917105033.
6
Immune-mediated cerebellar ataxias: from bench to bedside.
Cerebellum Ataxias. 2017 Sep 21;4:16. doi: 10.1186/s40673-017-0073-7. eCollection 2017.
7
Post-translational modifications of tubulin: pathways to functional diversity of microtubules.
Trends Cell Biol. 2015 Mar;25(3):125-36. doi: 10.1016/j.tcb.2014.10.004. Epub 2014 Nov 25.
8
Lysyl oxidases in the trabecular meshwork.
J Glaucoma. 2014 Oct-Nov;23(8 Suppl 1):S55-8. doi: 10.1097/IJG.0000000000000127.
9
Transglutaminase inhibition: A therapy to protect cells from death in neurodegeneration?
World J Biol Chem. 2012 Nov 26;3(11):184-6. doi: 10.4331/wjbc.v3.i11.184.
10
γ-Glutamylamines and neurodegenerative diseases.
Amino Acids. 2013 Jan;44(1):129-42. doi: 10.1007/s00726-011-1209-3. Epub 2012 Mar 10.

本文引用的文献

1
Gluten T cell epitope targeting by TG3 and TG6; implications for dermatitis herpetiformis and gluten ataxia.
Amino Acids. 2010 Nov;39(5):1183-91. doi: 10.1007/s00726-010-0554-y. Epub 2010 Mar 19.
2
Anti transglutaminase antibodies cause ataxia in mice.
PLoS One. 2010 Mar 15;5(3):e9698. doi: 10.1371/journal.pone.0009698.
3
Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders.
Physiol Rev. 2009 Jul;89(3):991-1023. doi: 10.1152/physrev.00044.2008.
5
Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase.
Ann Neurol. 2008 Sep;64(3):332-43. doi: 10.1002/ana.21450.
6
Tissue transglutaminase modulates alpha-synuclein oligomerization.
Protein Sci. 2008 Aug;17(8):1395-402. doi: 10.1110/ps.036103.108. Epub 2008 May 27.
7
Increased levels of gamma-glutamylamines in Huntington disease CSF.
J Neurochem. 2008 Jul;106(1):37-44. doi: 10.1111/j.1471-4159.2008.05350.x. Epub 2008 Jul 1.
9
Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia.
Neurology. 2006 Feb 14;66(3):373-7. doi: 10.1212/01.wnl.0000196480.55601.3a.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验